C-Type Natriuretic Peptide (CNP) (1-22), human TFA

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B ( NPR-B ) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor In Vitro C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human : Dose (nM/kg) AUC 0-∞ (pM·min/mL) MRT 0-∞ (min) T 1/2 (min) CL tot (mL/min/kg) Vd ss (mL/kg) 20 320±54 1.02±0.18 1.42±0.45 63.9±11.9 64.2±5.1 PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human : Dose (nM/kg) Cmax (pM/mL) Tmax (min) AUC 0-∞ (pM·min/mL) MRT 0-∞ (min) T 1/2 (min) BA (%) 50 9.02±3.74 5.0±0.0 152±73 13.9±3.4 10.0±5.0 19±9 Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL tot =total clearance, T 1/2 =half-life period, BA=bioavailability. i.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:NPR-B

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet